X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs ORCHID PHARMA LTD - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD ORCHID PHARMA LTD BIOCON LTD/
ORCHID PHARMA LTD
 
P/E (TTM) x 36.6 -0.8 - View Chart
P/BV x 4.9 0.6 870.3% View Chart
Dividend Yield % 1.5 0.0 -  

Financials

 BIOCON LTD   ORCHID PHARMA LTD
EQUITY SHARE DATA
    BIOCON LTD
Mar-16
ORCHID PHARMA LTD
Sep-13
BIOCON LTD/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs496194 255.5%   
Low Rs39735 1,132.9%   
Sales per share (Unadj.) Rs174.3276.5 63.0%  
Earnings per share (Unadj.) Rs44.8-79.2 -56.6%  
Cash flow per share (Unadj.) Rs56.9-43.5 -131.0%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs202.853.9 376.0%  
Shares outstanding (eoy) m200.0070.45 283.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.60.4 618.1%   
Avg P/E ratio x10.0-1.4 -688.8%  
P/CF ratio (eoy) x7.8-2.6 -297.4%  
Price / Book Value ratio x2.22.1 103.6%  
Dividend payout %11.20-   
Avg Mkt Cap Rs m89,2208,067 1,106.1%   
No. of employees `0004.42.8 157.7%   
Total wages/salary Rs m6,3632,527 251.8%   
Avg. sales/employee Rs Th7,894.56,956.1 113.5%   
Avg. wages/employee Rs Th1,441.2902.5 159.7%   
Avg. net profit/employee Rs Th2,029.7-1,993.0 -101.8%   
INCOME DATA
Net Sales Rs m34,85419,477 178.9%  
Other income Rs m845407 207.5%   
Total revenues Rs m35,69919,884 179.5%   
Gross profit Rs m8,2001,103 743.7%  
Depreciation Rs m2,4232,519 96.2%   
Interest Rs m1025,227 2.0%   
Profit before tax Rs m6,520-6,236 -104.6%   
Minority Interest Rs m-74420 -3,776.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5,754511 1,126.0%   
Tax Rs m2,569-125 -2,051.9%   
Profit after tax Rs m8,961-5,580 -160.6%  
Gross profit margin %23.55.7 415.6%  
Effective tax rate %39.42.0 1,962.6%   
Net profit margin %25.7-28.7 -89.7%  
BALANCE SHEET DATA
Current assets Rs m39,93211,014 362.6%   
Current liabilities Rs m16,27632,060 50.8%   
Net working cap to sales %67.9-108.1 -62.8%  
Current ratio x2.50.3 714.1%  
Inventory Days Days5495 56.5%  
Debtors Days Days8634 256.8%  
Net fixed assets Rs m39,10129,440 132.8%   
Share capital Rs m1,000705 141.9%   
"Free" reserves Rs m38,5912,043 1,889.3%   
Net worth Rs m40,5563,800 1,067.3%   
Long term debt Rs m20,7249,018 229.8%   
Total assets Rs m84,81646,510 182.4%  
Interest coverage x64.9-0.2 -33,617.2%   
Debt to equity ratio x0.52.4 21.5%  
Sales to assets ratio x0.40.4 98.1%   
Return on assets %10.7-0.8 -1,405.9%  
Return on equity %22.1-146.9 -15.0%  
Return on capital %19.0-3.7 -508.3%  
Exports to sales %30.737.9 81.2%   
Imports to sales %20.422.6 90.1%   
Exports (fob) Rs m10,7177,378 145.3%   
Imports (cif) Rs m7,1054,406 161.3%   
Fx inflow Rs m11,7897,513 156.9%   
Fx outflow Rs m8,3935,649 148.6%   
Net fx Rs m3,3961,865 182.1%   
CASH FLOW
From Operations Rs m5,2641,682 313.0%  
From Investments Rs m-9,540-9,860 96.8%  
From Financial Activity Rs m10,8676,644 163.6%  
Net Cashflow Rs m6,591-1,535 -429.4%  

Share Holding

Indian Promoters % 40.4 32.3 125.1%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 4.6 182.6%  
FIIs % 10.7 3.3 324.2%  
ADR/GDR % 0.0 4.6 -  
Free float % 19.9 55.3 36.0%  
Shareholders   109,995 84,811 129.7%  
Pledged promoter(s) holding % 0.0 54.9 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  TORRENT PHARMA  PLETHICO PHARMA  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Aug 18, 2017 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - FRESENIUS KABI ONCO. COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS